Key result
Structural modifications to the anthraquinone ring produce newer derivatives with improved anticancer properties, increased potency, selectivity, and reduced toxicity.
Why the study?
Clinical use of anthraquinone antibiotics is limited by toxicities such as cardiomyopathy, motivating chemical modifications to develop potent anticancer agents with fewer adverse effects.
Subtle chemical modifications and molecular hybridization of anthraquinones offer a promising strategy to develop potent anticancer agents with reduced cardiotoxicity.
Authors
No takes yet. Share an insight, caveat, or question.
Anthraquinone modifications may reduce cardiomyopathy risk in cancer therapy; leaves open need for clinical validation of novel analogs.
Mishra et al. (2025) conducted a review in Cancer. Anthraquinone derivatives was evaluated. Structural modifications to the anthraquinone ring produce newer derivatives with improved anticancer properties, increased potency, selectivity, and reduced toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: